Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

FDA approves Pfizer’s RSV vaccine for maternal use

by Laura Howes
August 26, 2023 | A version of this story appeared in Volume 101, Issue 28

 

On Aug. 21, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, to protect infants. The protein-based vaccine is given to pregnant people at a late stage in gestation, and the immunity they develop is passed to the child before birth. This is the latest in a run of RSV-related approvals. In May, the FDA approved Abrysvo and GSK’s Arexvy for use in patients over 60, and in July it approved the monoclonal antibody Beyfortus (nirsevimab) for infants.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.